Navigation Links
Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
Date:1/5/2012

EAST BRUNSWICK, N.J., Jan. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Noble Financial Capital Markets Eighth Annual Equity Conference on Tuesday, January 17, 2012 at 10:00 AM Eastern Time.  The conference will be held at the Seminole Hard Rock Hotel in Hollywood, Florida.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT - GContact:  Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan information@savient.com 

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006 

 


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
2. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
3. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
4. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
5. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
6. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
7. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
8. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
10. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
11. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... -- The blood testing market in China ... and The Freedonia Group in a recent report.  The ... healthcare research firm said that China ... and in improving testing at the provincial level.   The ... Blood Testing Market in China , which utilized ...
Breaking Medicine Technology:
(Date:4/29/2016)... Springs, California (PRWEB) , ... April 29, 2016 ... ... lies at the heart of our nation’s productivity, stability, even security. Most importantly, ... for their organizations. , Then why are American workers so unhappy? , Just ...
(Date:4/29/2016)... ... ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual “Bite Back Against ... breeze and temperatures in the 60s. Over 400 runners, walkers and volunteers participated in ... 1-mile walk were held to increase awareness about Lyme disease and to raise funds ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one ... to improve smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering ... patients to learn more about the options currently available to them and which ones ...
Breaking Medicine News(10 mins):